Autoplaque vs CVI42
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary focus is on highly specialized, AI-powered quantitative analysis of coronary plaques and luminal stenoses derived specifically from CT angiography images. This tool is ideal for clinicians seeking precise measurements for heart attack risk prediction and treatment guidance, particularly when detailed plaque characterization and stenosis quantification from CT are paramount. Its workstation-based deployment is well-suited for dedicated coronary CT analysis workflows.
View Autoplaque →Choose CVI42 if…
Choose CVI42 if you require a comprehensive, AI-enabled software platform capable of advanced cardiac and vascular imaging analysis across both CT and MRI modalities. This solution is best suited for institutions needing a unified system for diverse diagnostic, planning, and patient care workflows, including advanced CMR automation, broad coronary plaque characterization (calcified, non-calcified, low-attenuation), and vascular CT analysis. Its on-premise deployment supports integration into larger imaging departments handling multiple cardiac imaging types.
View CVI42 →For a physician evaluating AI tools for cardiac imaging, Autoplaque and CVI42 offer distinct strengths. Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared, workstation-based software specifically designed for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. It excels at automated vessel, plaque, and lumen segmentation, providing detailed measurements of vessel diameter and area. This tool is best suited for cardiologists or radiologists primarily focused on precise coronary plaque characterization and stenosis measurement to aid in risk prediction and treatment guidance.
In contrast, CVI42 by Circle Cardiovascular Imaging is an AI-enabled, on-premise platform offering a broader suite of tools for comprehensive cardiac and vascular imaging analysis across both CT and MRI. While it includes AI-automated coronary lumen and wall segmentation and comprehensive plaque analysis, it also provides advanced CMR automation (like T1 mapping and 4D flow pre-processing) and vascular CT analysis. The key practical difference lies in their scope: Autoplaque is a specialized tool for coronary CTA plaque analysis, while CVI42 is a more versatile platform for a wider range of cardiac and vascular imaging needs. Physicians requiring a dedicated, in-depth coronary plaque analysis solution should consider Autoplaque. Those needing a comprehensive platform for various cardiac and vascular imaging modalities, including advanced MRI features, would find CVI42 more appropriate.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | CVI42 |
|---|---|---|
| Pricing | Not disclosed | Contact for pricing |
| Deployment | Workstation-based software, runs on Windows or Mac computer platforms | On-premise solution |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CVI42CVI42 offers a unified platform for various cardiac imaging modalities (MR, CT, structural heart, EP) and flexible deployment options (standalone workstation or Client/Server), providing a consistent and streamlined user experience across a wider range of clinical needs. Autoplaque is workstation-based for Windows or Mac, focusing primarily on CT angiography analysis, which is less versatile for a multi-modality environment [JSON].
Clinical Value
CVI42CVI42 provides a broader range of clinical capabilities, supporting both CT and MRI modalities with advanced features like CMR automation (T1 mapping, 4D flow), vascular CT analysis, and research-use PCAT analysis, in addition to comprehensive coronary plaque analysis [JSON, cite: 1, 20]. While Autoplaque is FDA-cleared for quantitative CT angiography plaque analysis and heart attack risk prediction, its scope is more focused on CT-specific coronary plaque [JSON].
Pricing & Value
CVI42Although neither tool discloses specific pricing, CVI42 offers a flexible subscription model that scales across CT and MR service lines, and it explicitly aligns with new Category I CPT codes for AI-enabled plaque analysis, facilitating reimbursement and revenue retention for healthcare providers [JSON, cite: 15, 20]. Autoplaque provides no information regarding its pricing structure or reimbursement strategies, making its value proposition less transparent [JSON].
Enterprise Readiness
CVI42CVI42 demonstrates strong enterprise readiness with its Client/Server deployment option, robust integration capabilities with PACS, EMR, DICOM, and HL7, and advanced security features like SSO and MFA. Its global adoption in over 1,700 hospitals further highlights its scalability and suitability for large healthcare systems. Autoplaque, being workstation-based, lacks the explicit enterprise-level integration and security details of CVI42 [JSON].
Innovation
CVI42CVI42 showcases a more expansive application of AI, extending beyond coronary plaque quantification to include advanced CMR automation (T1 mapping, 4D flow), vascular CT analysis, research-use PCAT analysis, and AI-enabled virtual device simulation for procedural planning [JSON, cite: 12, 20]. While Autoplaque leverages AI for quantitative plaque analysis and is backed by research, CVI42's broader multi-modality and diverse feature set suggest greater innovative scope [JSON, cite: 23, 26].
Support & Docs
CVI42CVI42 clearly outlines its support offerings, including phone and online support, and provides access to comprehensive documentation for various software versions. The company also highlights 'world class support' and 'industry-leading customer satisfaction scores'. Autoplaque's provided information does not detail its support channels or documentation availability, making it difficult to assess this dimension [JSON].
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | CVI42 |
|---|---|---|
| Company | Cedars-Sinai Medical Center: AIM | CIRCLE CARDIOVASCULAR IMAGING |
| Tagline | AI-Powered Quantitative Analysis for Coronary Plaque and Stenosis | One Platform for All Your Advanced Cardiac Imaging Needs |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Radiology | Cardiology, Cardiothoracic Surgery, Radiology |
| Primary Application/Focus | Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Comprehensive cardiac and vascular imaging analysis, enhancing diagnosis, planning, and patient care with advanced CT and MRI tools. |
| Plaque/Stenosis Analysis Detail | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician). | AI-automated coronary lumen and wall segmentation; Comprehensive coronary plaque analysis (calcified, non-calcified, low-attenuation); Automated detection of suspected coronary lesions. |
| Additional Advanced Features | Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area. | Advanced CMR automation (T1 mapping, 4D flow pre-processing); Vascular CT analysis and planning tools; Pericoronary Adipose Tissue (PCAT) analysis (research use only); 3D visualization and image fusion; Automated contouring of regions of interest. |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and CVI42.